Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway

Li,Tao; Guo,Ting; Liu,Houqin; Jiang,Hongtao; Wang,Yi

doi:10.3892/or.2020.7859

Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway

Authors:
- Tao Li
- Ting Guo
- Houqin Liu
- Hongtao Jiang
- Yi Wang
View Affiliations

Affiliations: Department of Transplantation, The Second Affiliated Hospital of Hainan Medical University, Transplantation Institute of Hainan Medical University, Haikou, Hainan 570105, P.R. China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Division of Gastrointestinal Cancer Translational Research Laboratory, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
Published online on: November 19, 2020 https://doi.org/10.3892/or.2020.7859
Pages: 83-94
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Platelet‑derived growth factor (PDGF) is a potent mitogen and chemoattractant that serves a role in the development of several types of solid cancer, and abnormal PDGF activity has been reported in numerous human tumors. Tumor‑derived PDGF ligands are considered to act in either a paracrine or autocrine manner, serving roles in the phosphorylation of receptors on tumor and stromal cells in the tumor microenvironment. Despite the well‑established association between PDGF and tumor progression, the precise mechanisms of autocrine PDGF signaling in pancreatic tumor cells remain elusive. Therefore, the present study aimed to analyze the influence of PDGF‑BB in pancreatic cancer. Pancreatic adenocarcinoma BxPC‑3 cells were cultured and treated with recombinant human PDGF‑BB in vitro. Cell proliferation was tested using an MTT assay. Cell apoptosis was measured using flow cytometry. Tumor cell migration and invasion were examined via wound‑healing and Transwell assays, respectively. The expression and subcellular localization of Yes‑associated protein (YAP) was determined using western blotting and immunofluorescence. The transcriptional activity of target genes was tested using a luciferase assay and reverse transcription‑quantitative PCR. The present study revealed that PDGF‑BB significantly promoted cell proliferation in pancreatic adenocarcinoma BxPC‑3 cells and enhanced the aggressiveness of this cell line, as demonstrated by Transwell and wound‑healing assays. Anoikis resistance is an important mechanism by which metastatic cells avoid apoptosis when detaching from adjacent cells or the extracellular matrix. PDGF‑BB treatment inhibited anoikis under anchorage‑independent conditions. Mechanistic experiments revealed that PDGF‑BB promoted the upregulation and activation of the transcriptional coactivator YAP, an effector of the Hippo signaling pathway. RhoA or protein phosphatase‑1 (PP‑1) inhibition partially abolished the accumulation and activation of YAP, suggesting PDGF‑BB‑mediated YAP dephosphorylation and transactivation via the RhoA/PP‑1 cascade. Pharmacologic inhibition of the PDGF receptor directly downregulated YAP activity and the expression levels of downstream genes. Furthermore, verteporfin, a small molecular inhibitor of the Hippo/YAP signaling pathway, partially reversed the effects of PDGF‑BB on cell proliferation, anoikis resistance and cell migration. In conclusion, the present study revealed that the Hippo/YAP signaling pathway may be involved in the tumor‑promoting activity of PDGF‑BB in pancreatic cancer.

View Figures

View References

1	Bartoschek M and Pietras K: PDGF family function and prognostic value in tumor biology. Biochem Biophys Res Commun. 503:984–990. 2018. View Article : Google Scholar
2	Heldin CH: Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal. 11:972013. View Article : Google Scholar
3	Fredriksson L, Li H and Eriksson U: The PDGF family: Four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 15:197–204. 2004. View Article : Google Scholar
4	Roskoski R Jr: The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. Pharmacol Res. 129:65–83. 2018. View Article : Google Scholar
5	Heldin CH, Lennartsson J and Westermark B: Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis. J Intern Med. 283:16–44. 2018. View Article : Google Scholar
6	Cao Y: Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol Med. 19:460–473. 2013. View Article : Google Scholar
7	Martinho O, Longatto-Filho A, Lambros MB, Martins A, Pinheiro C, Silva A, Pardal F, Amorim J, Mackay A, Milanezi F, et al: Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer. 101:973–982. 2009. View Article : Google Scholar
8	Nazarenko I, Hede SM, He X, Hedrén A, Thompson J, Lindström MS and Nistér M: PDGF and PDGF receptors in glioma. Ups J Med Sci. 117:99–112. 2012. View Article : Google Scholar
9	Saito Y, Haendeler J, Hojo Y, Yamamoto K and Berk BC: Receptor heterodimerization: Essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol. 21:6387–6394. 2001. View Article : Google Scholar
10	Andrae J, Gallini R and Betsholtz C: Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22:1276–1312. 2008. View Article : Google Scholar
11	Paulsson J, Sjöblom T, Micke P, Pontén F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirström K and Ostman A: Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol. 175:334–341. 2009. View Article : Google Scholar
12	Dhar K, Dhar G, Majumder M, Haque I, Mehta S, Van Veldhuizen PJ, Banerjee SK and Banerjee S: Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1. Mol Cancer. 9:2092010. View Article : Google Scholar
13	Krenzlin H, Behera P, Lorenz V, Passaro C, Zdioruk M, Nowicki MO, Grauwet K, Zhang H, Skubal M, Ito H, et al: Cytomegalovirus promotes murine glioblastoma growth via pericyte recruitment and angiogenesis. J Clin Invest. 129:1671–1683. 2019. View Article : Google Scholar
14	Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 15:275–286. 2004. View Article : Google Scholar
15	Heldin CH: Autocrine PDGF stimulation in malignancies. Ups J Med Sci. 117:83–91. 2012. View Article : Google Scholar
16	Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C and Negri E: European cancer mortality predictions for the year 2015: Does lung cancer have the highest death rate in EU women? Ann Oncol. 26:779–786. 2015. View Article : Google Scholar
17	Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M and Andersson R: Pancreatic cancer: Yesterday, today and tomorrow. Future Oncol. 12:1929–1946. 2016. View Article : Google Scholar
18	Frisch SM and Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol. 13:555–562. 2001. View Article : Google Scholar
19	Gupta P, Gupta N, Fofaria NM, Ranjan A and Srivastava SK: HER2-mediated GLI2 stabilization promotes anoikis resistance and metastasis of breast cancer cells. Cancer Lett. 442:68–81. 2019. View Article : Google Scholar
20	Khader S, Thyagarajan A and Sahu RP: Exploring signaling pathways and pancreatic cancer treatment approaches using genetic models. Mini Rev Med Chem. 19:1112–1125. 2019. View Article : Google Scholar
21	Bai Y, Bai Y, Dong J, Li Q, Jin Y, Chen B and Zhou M: Hedgehog signaling in pancreatic fibrosis and cancer. Medicine (Baltimore). 95:e29962016. View Article : Google Scholar
22	Fjällskog ML, Hessman O, Eriksson B and Janson ET: Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol. 46:741–746. 2007. View Article : Google Scholar
23	Yuzawa S, Kano MR, Einama T and Nishihara H: PDGFRβ expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker. Med Oncol. 29:2824–2830. 2012. View Article : Google Scholar
24	Abe M, Kortylewicz ZP, Enke CA, Mack E and Baranowska-Kortylewicz J: Activation of PDGFr-β signaling pathway after imatinib and radioimmunotherapy treatment in experimental pancreatic cancer. Cancers (Basel). 3:2501–2515. 2011. View Article : Google Scholar
25	Weissmueller S, Manchado E, Saborowski M, Morris JP IV, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, et al: Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell. 157:382–394. 2014. View Article : Google Scholar
26	Kuo TL, Cheng KH, Shan YS, Chen LT and Hung WC: β-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer. Theranostics. 9:324–336. 2019. View Article : Google Scholar
27	Su A, He S, Tian B, Hu W and Zhang Z: MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells. PLoS One. 8:e713092013. View Article : Google Scholar
28	Hiram-Bab S, Katz LS, Shapira H, Sandbank J, Gershengorn MC and Oron Y: Platelet-derived growth factor BB mimics serum-induced dispersal of pancreatic epithelial cell clusters. J Cell Physiol. 229:743–751. 2014. View Article : Google Scholar
29	Lee J, Lee J, Yun JH, Choi C, Cho S, Kim SJ and Kim JH: Autocrine DUSP28 signaling mediates pancreatic cancer malignancy via regulation of PDGF-A. Sci Rep. 7:127602017. View Article : Google Scholar
30	Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D, et al: An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun. 357:1142–1147. 2007. View Article : Google Scholar
31	Moench R, Grimmig T, Kannen V, Tripathi S, Faber M, Moll EM, Chandraker A, Lissner R, Germer CT, Waaga-Gasser AM and Gasser M: Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer. Oncotarget. 7:68749–68767. 2016. View Article : Google Scholar
32	Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, et al: Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 8:3102017. View Article : Google Scholar
33	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
34	Jenning S, Pham T, Ireland SK, Ruoslahti E and Biliran H: Bit1 in anoikis resistance and tumor metastasis. Cancer Lett. 333:147–151. 2013. View Article : Google Scholar
35	Ou C, Sun Z, Li S, Li G, Li X and Ma J: Dual roles of yes-associated protein (YAP) in colorectal cancer. Oncotarget. 8:75727–75741. 2017. View Article : Google Scholar
36	Hussein MR, Haemel AK and Wood GS: Apoptosis and melanoma: Molecular mechanisms. J Pathol. 199:275–288. 2003. View Article : Google Scholar
37	Lu J, Yang Y, Guo G, Liu Y, Zhang Z, Dong S, Nan Y, Zhao Z, Zhong Y and Huang Q: IKBKE regulates cell proliferation and epithelial-mesenchymal transition of human malignant glioma via the Hippo pathway. Oncotarget. 8:49502–49514. 2017. View Article : Google Scholar
38	Zygulska AL, Krzemieniecki K and Pierzchalski P: Hippo pathway-brief overview of its relevance in cancer. J Physiol Pharmacol. 68:311–335. 2017.
39	Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnow CA and Pan D: A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev. 28:432–437. 2014. View Article : Google Scholar
40	Piccolo S, Dupont S and Cordenonsi M: The biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev. 94:1287–1312. 2014. View Article : Google Scholar
41	Zanconato F, Cordenonsi M and Piccolo S: YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016. View Article : Google Scholar
42	Hansen CG, Moroishi T and Guan KL: YAP and TAZ: A nexus for Hippo signaling and beyond. Trends Cell Biol. 25:499–513. 2015. View Article : Google Scholar
43	Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, et al: YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell. 158:157–170. 2014. View Article : Google Scholar
44	Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M, Deshpande V, et al: YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Rep. 10:1692–1707. 2015. View Article : Google Scholar
45	Yuan WC, Pepe-Mooney B, Galli GG, Dill MT, Huang HT, Hao M, Wang Y, Liang H, Calogero RA and Camargo FD: NUAK2 is a critical YAP target in liver cancer. Nat Commun. 9:48342018. View Article : Google Scholar
46	Park JA and Kwon YG: Hippo-YAP/TAZ signaling in angiogenesis. BMB Rep. 51:157–162. 2018. View Article : Google Scholar
47	Zhao B, Li L, Tumaneng K, Wang CY and Guan KL: A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP). Genes Dev. 24:72–85. 2010. View Article : Google Scholar
48	Lee YA, Noon LA, Akat KM, Ybanez MD, Lee TF, Berres ML, Fujiwara N, Goossens N, Chou HI, Parvin-Nejad FP, et al: Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nat Commun. 9:49622018. View Article : Google Scholar
49	Ansari D, Ohlsson H, Althini C, Bauden M, Zhou Q, Hu D and Andersson R: The Hippo signaling pathway in pancreatic cancer. Anticancer Res. 39:3317–3321. 2019. View Article : Google Scholar
50	Ben Mimoun S and Mauviel A: Molecular mechanisms underlying TGF-β/Hippo signaling crosstalks - Role of baso-apical epithelial cell polarity. Int J Biochem Cell Biol. 98:75–81. 2018. View Article : Google Scholar
51	Dobrokhotov O, Samsonov M, Sokabe M and Hirata H: Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms. Clin Transl Med. 7:232018. View Article : Google Scholar
52	Totaro A, Panciera T and Piccolo S: YAP/TAZ upstream signals and downstream responses. Nat Cell Biol. 20:888–899. 2018. View Article : Google Scholar
53	Pei T, Li Y, Wang J, Wang H, Liang Y, Shi H, Sun B, Yin D, Sun J, Song R, et al: YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget. 6:17206–17220. 2015. View Article : Google Scholar
54	Gibault F, Corvaisier M, Bailly F, Huet G, Melnyk P and Cotelle P: Non-photoinduced biological properties of verteporfin. Curr Med Chem. 23:1171–1184. 2016. View Article : Google Scholar
55	Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong J, Sun X and Li J: Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci. 108:478–487. 2017. View Article : Google Scholar
56	Yang S, Zhang L, Purohit V, Shukla SK, Chen X, Yu F, Fu K, Chen Y, Solheim J, Singh PK, et al: Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget. 6:36019–36031. 2015. View Article : Google Scholar
57	Yamaguchi R, Lartigue L and Perkins G: Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Pharmacol Ther. 195:13–20. 2019. View Article : Google Scholar
58	Boisvert-Adamo K, Longmate W, Abel EV and Aplin AE: Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res. 7:549–556. 2009. View Article : Google Scholar
59	Su H, Si XY, Tang WR and Luo Y: The regulation of anoikis in tumor invasion and metastasis. Yi Chuan. 35:10–16. 2013.(In Chinese). View Article : Google Scholar
60	Jang JW, Kim MK and Bae SC: Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway. Small GTPases. 11:280–288. 2018. View Article : Google Scholar
61	Zhang J, Lauf PK and Adragna NC: PDGF activates K-Cl cotransport through phosphoinositide 3-kinase and protein phosphatase-1 in primary cultures of vascular smooth muscle cells. Life Sci. 77:953–965. 2005. View Article : Google Scholar
62	Li L, Li J, Wang JY, Yang CQ, Jia ML and Jiang W: Role of RhoA in platelet-derived growth factor-BB-induced migration of rat hepatic stellate cells. Chin Med J (Engl). 123:2502–2509. 2010.
63	Smoot RL, Werneburg NW, Sugihara T, Hernandez MC, Yang L, Mehner C, Graham RP, Bronk SF, Truty MJ and Gores GJ: Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation. J Cell Biochem. 119:824–836. 2018. View Article : Google Scholar
64	Wu LMN, Deng Y, Wang J, Zhao C, Wang J, Rao R, Xu L, Zhou W, Choi K, Rizvi TA, et al: Programming of schwann cells by Lats1/2-TAZ/YAP signaling drives malignant peripheral nerve sheath tumorigenesis. Cancer Cell. 33:292–308.e7. 2018. View Article : Google Scholar